Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: Similarities and differences

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 4, 2009, Pages 411-420

  Montani, David ^a   Kemp, Kristina ^a   Dorfmuller, Peter ^a   Sitbon, Olivier ^a   Simonneau, Gérald ^a   Humbert, Marc ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Alveolar hemorrhage; Carbon monoxide diffusing capacity; Computed tomography; Pulmonary arterial hypertension; Pulmonary veno occlusive disease

Indexed keywords

CARBON MONOXIDE; POLYCYCLIC AROMATIC HYDROCARBON;

ARTERIAL GAS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HEMODYNAMICS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG EDEMA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG HEMORRHAGE; LUNG LAVAGE; LUNG TRANSPLANTATION; OXYGEN SATURATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; RISK FACTOR;

BIOPSY; BLOOD GAS ANALYSIS; BRONCHOALVEOLAR LAVAGE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; MALE; PROGNOSIS; PULMONARY VENO-OCCLUSIVE DISEASE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68049113686     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1233310     Document Type: Review

References (79)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117
2. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12, Suppl S):5S-12S
3. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(12, Suppl S):25S-32S (Pubitemid 38759714)
4. Lantuéjoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006;30:850-857 (Pubitemid 44264975)
5. Wagenvoort CA. The pathology of primary pulmonary hypertension. J Pathol 1970;101(4):Pi
6. Rabiller A, Jaïs X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006;27:108-113 (Pubitemid 43092673)
7. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000;162:1964-1973
8. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary venoocclusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87:220-233
9. Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000;118:1671-1679 (Pubitemid 32001794)
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030
11. Humbert M, Nunes H, Sitbon O, Parent F, Hervé P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-475 (Pubitemid 32912079)
12. Abenhaim L, Moride Y, Brenot F, et al; International Primary Pulmonary Hypertension Study Group. Appetitesuppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-616
13. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008;31:343-348
14. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981;283:881-883
15. Gurtner HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 1985;27:160-171
16. Joselson R, Warnock M. Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 1983;14:88-91
17. Knight BK, Rose AG. Pulmonary veno-occlusive disease after chemotherapy. Thorax 1985;40:874-875
18. Swift GL, Gibbs A, Campbell IA, Wagenvoort CA, Tuthill D. Pulmonary veno-occlusive disease and Hodgkin's lymphoma. Eur Respir J 1993;6:596-598 (Pubitemid 23135201)
19. Waldhorn RE, Tsou E, Smith FP, Kerwin DM. Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984;12:394-396 (Pubitemid 15221514)
20. Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989;47:989-992 (Pubitemid 19161834)
21. Williams LM, Fussell S, Veith RW, Nelson S, Mason CM. Pulmonary veno-occlusive disease in an adult following bone marrow transplantation: case report and review of the literature. Chest 1996;109:1388-1391 (Pubitemid 26000299)
22. Kuga T, Kohda K, Hirayama Y, et al. Pulmonary venoocclusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol 1996;64:143-150 (Pubitemid 26281432)
23. Troussard X, Bernaudin JF, Cordonnier C, et al. Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax 1984;39:956-957 (Pubitemid 15211838)
24. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF. Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant 1996;18:755-760 (Pubitemid 26361364)
25. Seguchi M, Hirabayashi N, Fujii Y, et al. Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 2000;69:177-179 (Pubitemid 30062627)
26. Trobaugh-Lotrario AD, Greffe B, Deterding R, Deutsch G, Quinones R. Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol 2003;25:405-409 (Pubitemid 36569974)
27. Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant 2008;41:677-686
28. Wright JL, Tai H, Churg A. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. Am J Respir Cell Mol Biol 2004;31:501-509 (Pubitemid 39463398)
29. Wright JL, Tai H, Churg A. Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig. J Appl Physiol 2006;100:672-678 (Pubitemid 43671624)
30. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007;38:893-902 (Pubitemid 46735956)
31. Zhang L, Visscher D, Rihal C, Aubry MC. Pulmonary venoocclusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease. Rheumatol Int 2007;27:1163-1165 (Pubitemid 47373945)
32. Johnson SR, Patsios D, Hwang DM, Granton JT. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006;33:2347-2350 (Pubitemid 44749800)
33. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006;61:68-74 (Pubitemid 43106981)
34. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000;161:216-223
35. Hamada K, Teramoto S, Narita N, Yamada E, Teramoto K, Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000;15:421-423 (Pubitemid 30085976)
36. Escamilla R, Hermant C, Berjaud J, Mazerolles C, Daussy X. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995;8:1982-1984
37. Hourseau M, Capron F, Nunes H, Godmer P, Martin A, Kambouchner M. Pulmonary veno-occlusive disease in a patient with HIV infection: a case report with autopsy findings [in French]. Ann Pathol 2002;22:472-475 (Pubitemid 36168563)
38. Ruchelli ED, Nojadera G, Rutstein RM, Rudy B. Pulmonary veno-occlusive disease: another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med 1994;118:664-666
39. Rosenzweig EB, Morse JH, Knowles JA, et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008;27:668-674
40. Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177:1377-1383 (Pubitemid 351860916)
41. Humbert M. Update in pulmonary hypertension 2008. Am J Respir Crit Care Med 2009;179:650-656
42. Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003;167:889-894 (Pubitemid 36801778)
43. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-132 (Pubitemid 43238027)
44. Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006;27:212-213
45. Davies P, Reid L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum Pathol 1982;13:911-915
46. Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977;32:763-766
47. Dufour B, Maître S, Humbert M, Capron F, Simonneau G, Musset D. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998;171:1321-1324 (Pubitemid 28489421)
48. Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004;183:65-70 (Pubitemid 38789013)
49. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436
50. Montani D, Price LC, Dorfmuller P, et al. Pulmonary venoocclusive disease. Eur Respir J 2009;33:189-200
51. Rambihar VS, Fallen EL, Cairns JA. Pulmonary venoocclusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings. Can Med Assoc J 1979;120:1519-1522
52. Gaar KA Jr, Taylor AE, Owens LJ, Guyton AC. Pulmonary capillary pressure and filtration coefficient in the isolated perfused lung. Am J Physiol 1967;213:910-914
53. Grimbert FA. Effective pulmonary capillary pressure. Eur Respir J 1988;1:297-301
54. Cope DK, Allison RC, Parmentier JL, Miller JN, Taylor AE. Measurement of effective pulmonary capillary pressure using the pressure profile after pulmonary artery occlusion. Crit Care Med 1986;14:16-22
55. Fesler P, Pagnamenta A, Vachiéry JL, et al. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J 2003;21:31-36 (Pubitemid 36150297)
56. Souza R, Amato MB, Demarzo SE, et al. Pulmonary capillary pressure in pulmonary hypertension. Crit Care 2005;9:R132-R138
57. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111 (Pubitemid 40847788)
58. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary venoocclusive disease. Chest 1998;113:237-240 (Pubitemid 28044953)
59. Swensen SJ, Tashjian JH, Myers JL, et al. Pulmonary venoocclusive disease: CT findings in eight patients. AJR Am J Roentgenol 1996;167:937-940 (Pubitemid 26322248)
60. Elliott CG, Colby TV, Hill T, Crapo RO. Pulmonary venoocclusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. Respiration 1988;53:262-266 (Pubitemid 18196941)
61. Matthews AW, Buchanan R. A case of pulmonary venoocclusive disease and a new bronchoscopic sign. Respir Med 1990;84:503-505 (Pubitemid 20387045)
62. Ohmichi M, Tagaki S, Nomura N, Tsunematsu K, Suzuki A. Endobronchial changes in chronic pulmonary venous hypertension. Chest 1988;94:1127-1132 (Pubitemid 19002768)
63. Wahidi MM, Rocha AT, Hollingsworth JW, Govert JA, Feller-Kopman D, Ernst A. Contraindications and safety of transbronchial lung biopsy via flexible bronchoscopy: a survey of pulmonologists and review of the literature. Respiration 2005;72:285-295 (Pubitemid 40981088)
64. Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974;364:69-79
65. Chazova I, Robbins I, Loyd J, et al. Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis. Eur Respir J 2000;15:116-122 (Pubitemid 30068946)
66. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008;58:521-531 (Pubitemid 351294886)
67. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-189 (Pubitemid 44116858)
68. Barst RJ, Rubin LJ, Long WA, et al; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302
69. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788 (Pubitemid 34925627)
70. Okumura H, Nagaya N, Kyotani S, et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 2002;122:1096-1098
71. Resten A, Maître S, Humbert M, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002;222:782-788 (Pubitemid 34215230)
72. Davis LL, deBoisblanc BP, Glynn CE, Ramirez C, Summer WR. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995;108:1754-1756
73. Montani D, Jaïs X, Price LC, et al. Cautious use of epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009;June 18 [Epub ahead of print]
74. Shackelford GD, Sacks EJ, Mullins JD, McAlister WH. Pulmonary venoocclusive disease: case report and review of the literature. AJR Am J Roentgenol 1977;128:643-648 (Pubitemid 8077775)
75. Hoeper MM, Eschenbruch C, Zink-Wohlfart C, et al. Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Respir Med 1999;93:62-64 (Pubitemid 29043946)
76. Kuroda T, Hirota H, Masaki M, et al. Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease. Heart Lung Circ 2006;15:139-142
77. Barreto AC, Franchi SM, Castro CR, Lopes AA. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res 2005;38:185-195 (Pubitemid 40372594)
78. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis 2002;45:115-128 (Pubitemid 35253678)
79. Cassart M, Gevenois PA, Kramer M, et al. Pulmonary venoocclusive disease: CT findings before and after single-lung transplantation. AJR Am J Roentgenol 1993;160:759-760 (Pubitemid 23109969)